Ocular Therapeutix, Inc (OCUL) stock
Close on Nov 17, 2026Market cap $1.32BP/E –Yield –
Earnings
Ocular Therapeutix's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Ocular Therapeutix's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 4, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 9, 2026before the open | $12.90M | -11.0% | -$0.42 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 3, 2026before the open | $13.50M | 0.0% | -$0.35 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 5, 2026before the open | $10.80M | +0.9% | -$0.40 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 5, 2026before the open | $13.30M | -22.2% | -$0.29 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 4, 2025before the open | $14.50M | -5.8% | -$0.38 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 5, 2025before the open | $13.50M | -17.7% | -$0.39 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 5, 2025before the open | $10.70M | -27.7% | -$0.38 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 3, 2025before the open | $17.10M | +15.5% | -$0.29 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 14, 2024before the open | $15.40M | +2.0% | -$0.22 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 7, 2024before the open | $16.40M | +7.9% | -$0.26 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 7, 2024after the close | $14.80M | +10.4% | -$0.49 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 11, 2024after the close | $14.80M | +5.0% | -$0.35 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 7, 2023after the close | $15.10M | +25.8% | -$0.25 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 7, 2023after the close | $15.20M | +23.6% | -$0.26 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 8, 2023after the close | $13.40M | +1.5% | -$0.39 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 6, 2023after the close | $14.10M | +14.6% | -$0.24 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 7, 2022after the close | $12.00M | -1.6% | -$0.31 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 8, 2022after the close | $12.30M | – | -$0.25 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 9, 2022after the close | $13.20M | – | -$0.22 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 28, 2022after the close | $12.30M | – | -$0.23 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 8, 2021after the close | $12.20M | – | -$0.23 | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 22, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 29, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 11, 2021after the close | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 7, 2020before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
No open guidance: every period Ocular Therapeutix guided for has been reported
Guidance history
Every forecast Ocular Therapeutix put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 14, 2024 | total net revenues for DEXTENZA | FY2024 | $62.00M – $67.00M | Reaffirmed |
| Aug 7, 2024 | total net revenues for DEXTENZA | FY2024 | $62.00M – $67.00M | New |
| Nov 7, 2023 | DEXTENZA net product revenue | FY2023 | $55.00M – $60.00M | Reaffirmed |
| Aug 7, 2023 | DEXTENZA net product revenue | FY2023 | $55.00M – $60.00M | Reaffirmed |
| May 8, 2023 | Net product revenue | FY2023 | $55.00M – $60.00M | Reaffirmed |
| Mar 6, 2023 | Net product revenue | FY2023 | $55.00M – $60.00M | New |
| Nov 7, 2022 | Total net product revenue | FY2022 | $48.00M – $52.00M | Lowered |
| Aug 8, 2022 | Total net product revenue | FY2022 | $55.00M – $60.00M | Reaffirmed |
| May 9, 2022 | Total net product revenue | FY2022 | $55.00M – $60.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Ocular Therapeutix filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- News
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- News
See a number that looks wrong?